Clinical Trial Update: Reboxetine Adjuvant Therapy for the Treatment of Schizophrenia [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating Reboxetine as adjuvant therapy for schizophrenia; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Reboxetine (Reboxetine)

Snippet

Sponsor: Abarbanel Mental Health Center | Conditions: Schizophrenia | Phase 1 | Status: UNKNOWN